|Articles|April 20, 2020

Charge Variant and Aggregation Analysis of Innovator and Biosimilars of Rituximab

Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.

Subscribe Now!

Trending on BioPharm International

Charge Variant and Aggregation Analysis of Innovator and Biosimilars of Rituximab

Newsletter

Related Content

Long-Term Performance and Stability of TOYOPEARL Super A over 200 Cleaning Cycles

Two-Step Monoclonal Antibody Purification Using a Multi-Column Continuous Chromatography Platform

Single-Use Components and Assemblies for Critical Bioprocess Steps and Various Biopharmaceutical Modalities: Including ADCs and More

Process Optimization for High Purity mAb Recovery

Unlocking the Future of RNA Manufacturing: A Guide to Enzymatic Synthesis

Trending on BioPharm International

FDA-Approved WAS Gene Therapy Hits Market in Nonprofit Model

Charles River Incubator Cohort to Accelerate CGT Development

FAQ: Shifts in FDA Regulations and Strategies in 2025

Two-Minute Mysteries: BioPharm Stories - Episode 2: The Costly Myth of Noninvasive Glucose Monitoring

Developing Next-Gen Cell Lines Using Targeted Integration